<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874432</url>
  </required_header>
  <id_info>
    <org_study_id>H-2008-0221</org_study_id>
    <secondary_id>A534280</secondary_id>
    <secondary_id>SMPH/MEDICINE/NEPHROLOGY</secondary_id>
    <nct_id>NCT00874432</nct_id>
  </id_info>
  <brief_title>Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease</brief_title>
  <official_title>Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this proposal is to investigate the potential for ACE-inhibitors (ACE-I)(drugs&#xD;
      primarily used to treat hypertension or congestive heart failure) to prevent or delay&#xD;
      cardiovascular disease (CVD) in older adults with chronic kidney disease (CKD) by examining&#xD;
      their impact on aortic stiffness in people with stage 3 CKD in a randomized, controlled&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be the first to examine whether aortic stiffness is increased in elderly&#xD;
      patients with CKD compared to their age-matched healthy controls and further examine whether&#xD;
      ACE-I may delay the progression of aortic stiffness in elderly CKD patients. If ACE-I therapy&#xD;
      appears beneficial in preventing or delaying arterial stiffening in elderly patients with&#xD;
      CKD, this work has important implications for improving the overall health of this&#xD;
      population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aortic Pulse Wave Velocity (PWV)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>PWV will be measured in patients over age 60 with stage 3 CKD and age matched controls without CKD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Vascular Stiffness As Measured by PWV</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Comparison between Participants with Stage 3 Chronic Kidney Disease (CKD) and age matched Controls without CKD. The numbers reported are the mean of all the participants in the group at two points in time - the baseline and at 12 months for CFPWV, CBPWV, and CRPWV.&#xD;
Carotid-Femoral Pulse Wave Velocity (CFPWV) Carotid-Brachial Pulse Wave Velocity (CBPWV) Carotid-Radial Pulse Wave Velocity (CRPWV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure From Baseline to 12 Months</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Change in Blood Pressure will be used to measure the effect of ACE-inhibitors on the clinical markers of Cardiovascular Disease in participants with stage 3 CKD.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Chronic Kidney Disease-ACE-I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ace inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Age matched control-ACE-I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ace-inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age matched control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>angiotensin converting enzyme inhibitor</intervention_name>
    <description>Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
    <arm_group_label>Age matched control</arm_group_label>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
    <other_name>ACE-inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisinopril</intervention_name>
    <description>1 x 40 mg per day</description>
    <arm_group_label>Age matched control-ACE-I</arm_group_label>
    <arm_group_label>Chronic Kidney Disease-ACE-I</arm_group_label>
    <other_name>ace inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 60 years&#xD;
&#xD;
          -  BP 120/80 or higher *(bps will be checked weekly first 4 weeks to ensure &lt; 130/80 - IF&#xD;
             bp remains &gt; 130/80 we will administer other bp meds per JNC VII guidelines)&#xD;
&#xD;
          -  CKD stage 3 (GFR 30 - 59 ml/min) for CKD group; no CKD for control group&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known significant CVD (history of Myocardial infarction (MI), recurrent stroke, or New&#xD;
             York Heart Association (NYHA) class III or greater).&#xD;
&#xD;
          -  Serum potassium &gt; 5.2 meq/L&#xD;
&#xD;
          -  Known allergy or hypersensitivity to ACE inhibitor or ARB&#xD;
&#xD;
          -  Female of childbearing age not practicing contraception&#xD;
&#xD;
          -  Current treatment with an Angiotensin Converting Enzyme Inhibitors (ACE-I) or&#xD;
             Angiotensin-Receptor Blockers (ARB) (Note: can participate if on ACE-I after 6 week&#xD;
             washout period)&#xD;
&#xD;
          -  History of ACE-I induced angioedema&#xD;
&#xD;
          -  History of angioedema, hereditary or idiopathic&#xD;
&#xD;
          -  Persons lacking consent capacity&#xD;
&#xD;
               -  500 mg/dL proteinuria on 2 consecutive spot urine protein/creat ratios&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjang Djamali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin-Madison School of Medicine and Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura Maursetter, DO</last_name>
    <role>Study Director</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin-Madison Hospitals and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ryan TP, Sloand JA, Winters PC, Corsetti JP, Fisher SG. Chronic kidney disease prevalence and rate of diagnosis. Am J Med. 2007 Nov;120(11):981-6.</citation>
    <PMID>17976426</PMID>
  </reference>
  <reference>
    <citation>Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998 Sep-Oct;11(5):239-45. Review.</citation>
    <PMID>9831236</PMID>
  </reference>
  <reference>
    <citation>Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001 Oct;38(4):938-42.</citation>
    <PMID>11641313</PMID>
  </reference>
  <reference>
    <citation>Covic A, Haydar AA, Bhamra-Ariza P, Gusbeth-Tatomir P, Goldsmith DJ. Aortic pulse wave velocity and arterial wave reflections predict the extent and severity of coronary artery disease in chronic kidney disease patients. J Nephrol. 2005 Jul-Aug;18(4):388-96.</citation>
    <PMID>16245242</PMID>
  </reference>
  <reference>
    <citation>London GM, Marchais SJ, Guerin AP. Arterial stiffness and function in end-stage renal disease. Adv Chronic Kidney Dis. 2004 Apr;11(2):202-9. Review.</citation>
    <PMID>15216492</PMID>
  </reference>
  <reference>
    <citation>Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis. 2005 Mar;45(3):494-501.</citation>
    <PMID>15754271</PMID>
  </reference>
  <reference>
    <citation>Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron Clin Pract. 2005;101(2):c47-52. Epub 2005 Jun 7. Review.</citation>
    <PMID>15942250</PMID>
  </reference>
  <reference>
    <citation>Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006 Feb 7;113(5):664-70.</citation>
    <PMID>16461839</PMID>
  </reference>
  <reference>
    <citation>London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, Metivier F. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996 Aug;50(2):600-8.</citation>
    <PMID>8840292</PMID>
  </reference>
  <reference>
    <citation>Shinohara K, Shoji T, Tsujimoto Y, Kimoto E, Tahara H, Koyama H, Emoto M, Ishimura E, Miki T, Tabata T, Nishizawa Y. Arterial stiffness in predialysis patients with uremia. Kidney Int. 2004 Mar;65(3):936-43.</citation>
    <PMID>14871413</PMID>
  </reference>
  <reference>
    <citation>Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension. 2004 Feb;43(2):163-8. Epub 2004 Jan 19. Review.</citation>
    <PMID>14732732</PMID>
  </reference>
  <reference>
    <citation>Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005 May 1;66(2):307-17. Review.</citation>
    <PMID>15820199</PMID>
  </reference>
  <reference>
    <citation>Ferrari AU, Radaelli A, Centola M. Invited review: aging and the cardiovascular system. J Appl Physiol (1985). 2003 Dec;95(6):2591-7. Review.</citation>
    <PMID>14600164</PMID>
  </reference>
  <reference>
    <citation>Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004 Jun;43(6):1239-45. Epub 2004 May 3.</citation>
    <PMID>15123572</PMID>
  </reference>
  <reference>
    <citation>Sawabe M, Takahashi R, Matsushita S, Ozawa T, Arai T, Hamamatsu A, Nakahara K, Chida K, Yamanouchi H, Murayama S, Tanaka N. Aortic pulse wave velocity and the degree of atherosclerosis in the elderly: a pathological study based on 304 autopsy cases. Atherosclerosis. 2005 Apr;179(2):345-51. Epub 2004 Dec 13.</citation>
    <PMID>15777552</PMID>
  </reference>
  <reference>
    <citation>London GM, Marchais SJ, Guerin AP, Pannier B. Arterial stiffness: pathophysiology and clinical impact. Clin Exp Hypertens. 2004 Oct-Nov;26(7-8):689-99. Review.</citation>
    <PMID>15702623</PMID>
  </reference>
  <reference>
    <citation>London GM, Marchais SJ, Guérin AP, Métivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens. 2005 Nov;14(6):525-31. Review.</citation>
    <PMID>16205470</PMID>
  </reference>
  <reference>
    <citation>Touyz RM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep. 2003 Apr;5(2):155-64. Review.</citation>
    <PMID>12642016</PMID>
  </reference>
  <reference>
    <citation>Unger T. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. J Renin Angiotensin Aldosterone Syst. 2001 Sep;2 Suppl 2:S4-7. Review.</citation>
    <PMID>11881101</PMID>
  </reference>
  <reference>
    <citation>Matsuda H, Hayashi K, Saruta T. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens. 2003 Apr;17(4):271-6.</citation>
    <PMID>12692572</PMID>
  </reference>
  <reference>
    <citation>Chrysant SG. Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J. 1998 Feb;135(2 Pt 2):S21-30. Review.</citation>
    <PMID>9488609</PMID>
  </reference>
  <reference>
    <citation>Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin. 2004 Oct;20(10):1559-69. Review.</citation>
    <PMID>15462689</PMID>
  </reference>
  <reference>
    <citation>Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004 Oct;44(4):398-404. Epub 2004 Aug 23.</citation>
    <PMID>15326093</PMID>
  </reference>
  <reference>
    <citation>Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002 Feb 27;287(8):1003-10.</citation>
    <PMID>11866648</PMID>
  </reference>
  <reference>
    <citation>Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997 Jul 1;96(1):308-15.</citation>
    <PMID>9236450</PMID>
  </reference>
  <reference>
    <citation>Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA. 2005 Jul 27;294(4):466-72.</citation>
    <PMID>16046653</PMID>
  </reference>
  <reference>
    <citation>Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 Jun 13;351(9118):1755-62.</citation>
    <PMID>9635947</PMID>
  </reference>
  <reference>
    <citation>Darne B, Girerd X, Safar M, Cambien F, Guize L. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension. 1989 Apr;13(4):392-400.</citation>
    <PMID>2522417</PMID>
  </reference>
  <reference>
    <citation>Mitchell GF, Lacourcière Y, Ouellet JP, Izzo JL Jr, Neutel J, Kerwin LJ, Block AJ, Pfeffer MA. Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation. 2003 Sep 30;108(13):1592-8. Epub 2003 Sep 15.</citation>
    <PMID>12975261</PMID>
  </reference>
  <reference>
    <citation>Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis. 2004 Jul;44(1):84-93.</citation>
    <PMID>15211442</PMID>
  </reference>
  <reference>
    <citation>Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005 Jun;67(6):2089-100.</citation>
    <PMID>15882252</PMID>
  </reference>
  <reference>
    <citation>McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR; ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005 Nov 1;46(9):1753-60. Epub 2005 Oct 10.</citation>
    <PMID>16256881</PMID>
  </reference>
  <reference>
    <citation>Mitchell GF, Izzo JL Jr, Lacourcière Y, Ouellet JP, Neutel J, Qian C, Kerwin LJ, Block AJ, Pfeffer MA. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation. 2002 Jun 25;105(25):2955-61.</citation>
    <PMID>12081987</PMID>
  </reference>
  <reference>
    <citation>Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar 13;160(5):685-93.</citation>
    <PMID>10724055</PMID>
  </reference>
  <reference>
    <citation>Djamali A, Sadowski E, Muehrer R, et al. Losartan Improves Renal Medullary Oxygenation and Oxidative Stress in Patients with Chronic Allograft Nephropathy. J.Am.Soc.Nephrol. 15 (Abstract Issue):SA-PO1026, 2004</citation>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 1, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <results_first_submitted>May 21, 2019</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disease</keyword>
  <keyword>angiotensin converting enzyme inhibitors</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>cardiovascular disease in elderly patients with CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred between January 2009 and May 2009. Patients were told about this study from the nephrologist or study coordinator around the time of their usual kidney clinic visit. Controls were enrolled through a group on campus who connects volunteers with research studies.</recruitment_details>
      <pre_assignment_details>There is limited data for this study, the PI is now in private practice and some raw data no longer exists to answer this outcome. We have done our due diligence to populate this record with data that remains.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chronic Kidney Disease-ACE-I</title>
          <description>ace inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
        </group>
        <group group_id="P2">
          <title>Chronic Kidney Disease</title>
          <description>angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
        </group>
        <group group_id="P3">
          <title>Age Matched Control-ACE-I</title>
          <description>ace-inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
        </group>
        <group group_id="P4">
          <title>Age Matched Control</title>
          <description>Placebo&#xD;
angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only data for Aim 1 of this study has been located.</population>
      <group_list>
        <group group_id="B1">
          <title>Chronic Kidney Disease-ACE-I</title>
          <description>ace inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
        </group>
        <group group_id="B2">
          <title>Chronic Kidney Disease</title>
          <description>angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
        </group>
        <group group_id="B3">
          <title>Age Matched Control-ACE-I</title>
          <description>ace-inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
        </group>
        <group group_id="B4">
          <title>Age Matched Control</title>
          <description>Placebo&#xD;
angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="63" upper_limit="68"/>
                    <measurement group_id="B2" value="87" lower_limit="74" upper_limit="90"/>
                    <measurement group_id="B3" value="63.4" lower_limit="61" upper_limit="75"/>
                    <measurement group_id="B4" value="67.3" lower_limit="62" upper_limit="79"/>
                    <measurement group_id="B5" value="68" lower_limit="61" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="17"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" spread="0.3"/>
                    <measurement group_id="B2" value="0.8" spread="1.8"/>
                    <measurement group_id="B3" value="NA" spread="NA">data no longer exists</measurement>
                    <measurement group_id="B4" value="NA" spread="NA">data no longer exists</measurement>
                    <measurement group_id="B5" value="NA" spread="NA">unable to calculate</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aortic Pulse Wave Velocity (PWV)</title>
        <description>PWV will be measured in patients over age 60 with stage 3 CKD and age matched controls without CKD.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Comparison of the baseline pulse wave velocity measures between the two groups (CKD vs no CKD) prior to intervention with ACE inhibitor. Data analyzed is from 32 participants due to drop out either from study self withdrawal (3) or ineligibility (1 = BP too low to start medication) and 7 without adequate testing data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease</title>
            <description>Participants over age 60 with Chronic Kidney Disease (CKD)</description>
          </group>
          <group group_id="O2">
            <title>Age Matched Control</title>
            <description>Healthy age-matched control over age 60</description>
          </group>
        </group_list>
        <measure>
          <title>Aortic Pulse Wave Velocity (PWV)</title>
          <description>PWV will be measured in patients over age 60 with stage 3 CKD and age matched controls without CKD.</description>
          <population>Comparison of the baseline pulse wave velocity measures between the two groups (CKD vs no CKD) prior to intervention with ACE inhibitor. Data analyzed is from 32 participants due to drop out either from study self withdrawal (3) or ineligibility (1 = BP too low to start medication) and 7 without adequate testing data available for analysis.</population>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Carotid-Femoral Pulse Wave Velocity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.90" spread="1.12"/>
                    <measurement group_id="O2" value="9.96" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carotid-Brachial Pulse Wave Velocity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" spread="1.76"/>
                    <measurement group_id="O2" value="8.57" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carotid-Radial Pulse Wave Velocity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" spread="2.12"/>
                    <measurement group_id="O2" value="8.38" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p-value for CBPWV between CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p-value for CRPWV between CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.739</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p-value for CFPWV between CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.471</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Vascular Stiffness As Measured by PWV</title>
        <description>Comparison between Participants with Stage 3 Chronic Kidney Disease (CKD) and age matched Controls without CKD. The numbers reported are the mean of all the participants in the group at two points in time - the baseline and at 12 months for CFPWV, CBPWV, and CRPWV.&#xD;
Carotid-Femoral Pulse Wave Velocity (CFPWV) Carotid-Brachial Pulse Wave Velocity (CBPWV) Carotid-Radial Pulse Wave Velocity (CRPWV)</description>
        <time_frame>baseline and 12 months</time_frame>
        <population>Participants in each arm that had measurements for both baseline and 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease-ACE-I</title>
            <description>ace inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease</title>
            <description>angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
          </group>
          <group group_id="O3">
            <title>Age Matched Control-ACE-I</title>
            <description>ace-inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
          </group>
          <group group_id="O4">
            <title>Age Matched Control</title>
            <description>Placebo&#xD;
angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Vascular Stiffness As Measured by PWV</title>
          <description>Comparison between Participants with Stage 3 Chronic Kidney Disease (CKD) and age matched Controls without CKD. The numbers reported are the mean of all the participants in the group at two points in time - the baseline and at 12 months for CFPWV, CBPWV, and CRPWV.&#xD;
Carotid-Femoral Pulse Wave Velocity (CFPWV) Carotid-Brachial Pulse Wave Velocity (CBPWV) Carotid-Radial Pulse Wave Velocity (CRPWV)</description>
          <population>Participants in each arm that had measurements for both baseline and 12 months</population>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CBPWV Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.87" spread="1.70"/>
                    <measurement group_id="O2" value="6.28" spread="NA">only one measurement</measurement>
                    <measurement group_id="O3" value="9.14" spread="0.82"/>
                    <measurement group_id="O4" value="8.17" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CBPWV 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.40" spread="2.50"/>
                    <measurement group_id="O2" value="8.28" spread="0.54"/>
                    <measurement group_id="O3" value="8.65" spread="1.87"/>
                    <measurement group_id="O4" value="8.06" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRPWV Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" spread="0.93"/>
                    <measurement group_id="O2" value="4.80" spread="NA">only one measurement</measurement>
                    <measurement group_id="O3" value="9.75" spread="0.95"/>
                    <measurement group_id="O4" value="8.95" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRPWV 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57" spread="2.03"/>
                    <measurement group_id="O2" value="8.66" spread="2.87"/>
                    <measurement group_id="O3" value="8.16" spread="1.93"/>
                    <measurement group_id="O4" value="9.43" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CFPWV Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.20" spread="0.99"/>
                    <measurement group_id="O2" value="7.95" spread="NA">only one measurement</measurement>
                    <measurement group_id="O3" value="9.96" spread="2.52"/>
                    <measurement group_id="O4" value="9.55" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CFPWV 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.07" spread="2.29"/>
                    <measurement group_id="O2" value="10.66" spread="2.78"/>
                    <measurement group_id="O3" value="8.33" spread="1.06"/>
                    <measurement group_id="O4" value="9.79" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This p-value compares the baseline CBPWV measures for the CKD vs Controls group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This p-value compares the 12 month CBPWV measures for the CKD vs Controls group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.869</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This p-value compares the baseline CRPWV measures for the CKD vs Controls group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.709</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This p-value compares the 12 month CBPWV measures for the CKD vs Controls group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.340</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This p-value compares the baseline CFPWV measures for the CKD vs Controls group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.730</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This p-value compares the 12 month CFPWV measures for the CKD vs Controls group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.204</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CBPWV measure of ACE-I CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.963</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CRPWV measure of ACE-I CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.991</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CFPWV measure of ACE-I CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.176</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CBPWV measure of the ACE-I CKD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.402</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CRPWV measure of the ACE-I CKD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.586</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CFPWV measure of the ACE-I CKD</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.455</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CBPWV measure of the ACE-I Control Group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.418</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CRPWV measure of the ACE-I Control Group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CFPWV measure of the ACE-I Control Group</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CBPWV measure of the CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.921</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CRPWV measure of the CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.887</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CFPWV measure of the CKD and Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.759</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CBPWV measure of the Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.851</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CRPWV measure of the Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.733</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the baseline and 12 month CFPWV measure of the Control groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.902</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CBPWV measure between the CKD ACE-I and CKD Control groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.414</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CRPWV measure between the CKD ACE-I and CKD Control groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.942</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CFPWV measure between the CKD ACE-I and CKD Control groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.990</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CBPWV measure between the ACE-I Control and CKD Control groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.273</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CRPWV measure between the ACE-I Control and CKD Control groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.516</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This compares the 12 month CFPWV measure between the ACE-I Control and CKD Control groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.102</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure From Baseline to 12 Months</title>
        <description>Change in Blood Pressure will be used to measure the effect of ACE-inhibitors on the clinical markers of Cardiovascular Disease in participants with stage 3 CKD.</description>
        <time_frame>up to 12 months</time_frame>
        <population>There is limited data for this study, the PI is now in private practice and the raw data no longer exists to answer this outcome. We have done our due diligence to populate this record with data that remains.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronic Kidney Disease-ACE-I</title>
            <description>ace inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Chronic Kidney Disease</title>
            <description>angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
          </group>
          <group group_id="O3">
            <title>Age Matched Control-ACE-I</title>
            <description>ace-inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
          </group>
          <group group_id="O4">
            <title>Age Matched Control</title>
            <description>Placebo&#xD;
angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Pressure From Baseline to 12 Months</title>
          <description>Change in Blood Pressure will be used to measure the effect of ACE-inhibitors on the clinical markers of Cardiovascular Disease in participants with stage 3 CKD.</description>
          <population>There is limited data for this study, the PI is now in private practice and the raw data no longer exists to answer this outcome. We have done our due diligence to populate this record with data that remains.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 12 months</time_frame>
      <desc>There is limited data for this study, the PI is now in private practice and unreachable. The remaining study team has found data only in support of Aim 1 (CKD aortic stiffness vs healthy controls), no data for ACE-I arms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chronic Kidney Disease-ACE-I</title>
          <description>ace inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
        </group>
        <group group_id="E2">
          <title>Chronic Kidney Disease</title>
          <description>angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
        </group>
        <group group_id="E3">
          <title>Age Matched Control-ACE-I</title>
          <description>ace-inhibitor&#xD;
lisinopril: 1 x 40 mg per day</description>
        </group>
        <group group_id="E4">
          <title>Age Matched Control</title>
          <description>Placebo&#xD;
angiotensin converting enzyme inhibitor: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stiff Neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lip Parasthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Uticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Low Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There is limited data for this study, the PI is now in private practice and some raw data no longer exists to answer this outcome. We have done our due diligence to populate this record with data that remains.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Arjang Djamali</name_or_title>
      <organization>University of Wisconsin - Madison</organization>
      <phone>(608) 262-9306</phone>
      <email>axd@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

